Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma

Table 1 Comparison of baseline clinical data between Group A and Group C

	Group A (n = 40)	Group C (n = 40)	t/χ2 value	P value
Gender (Male)	29	31	0.267	0.606
Age (yr)	62.82 ± 12.93	61.38 ± 10.29	0.551	0.583
Tumor size (cm)	3.75 ± 1.21	3.68 ± 1.17	0.263	0.793
Number of tumors			0.050	0.823
Single	22	21
2-3	18	19
Child-Pugh classification			0.054	0.816
A	26	25
B	14	15
TBiL (μmol/L)	18.28 ± 5.28	17.83 ± 5.16	0.583	0.562
AFP (ng/ml)	612.29 ± 127.38	625.93 ± 139.27	0.457	0.649
ALB (g/L)	37.19 ± 5.39	36.93 ± 5.33	0.217	0.829
ALT (U/L)	35.27 ± 15.14	36.42 ± 17.46	0.315	0.754
AST (U/L)	38.63 ± 15.13	40.41 ± 16.52	0.503	0.617

AFP: Alpha-fetoprotein; ALB: Serum albumin; ALT: Aminotransferase; AST: Aspartate aminotransferase; TBiL: Total bilirubin.

Table 2 Comparison of the efficacy between Group A and Group C at the 3^rd, 6^th, and 9^th month after treatment, n (%)

	3nd month		6th month		9th month
	Group A	Group C	Group A	Group C	Group A	Group C
CR	11 (27.5)	13 (32.5)	11 (27.5)	13 (32.5)	11 (27.5)	13 (32.5)
PR	14 (35.0)	15 (37.5)	14 (35.0)	15 (37.5)	14 (35.0)	15 (37.5)
SD	13 (32.5)	11 (27.5)	12 (30.0)	10 (25.0)	10 (25.0)	10 (25.0)
PD	2 (5.0)	1 (2.5)	3 (7.5)	2 (5.0)	4 (10.0)	2 (5.0)
Efficiency	25 (62.5)	28 (70.0)	25 (62.5)	28 (70.0)	25 (62.5)	28 (70.0)
χ2 value	0.701		0.583		0.855
P value	0.873		0.900		0.836

CR: Complete remission; PR: Partial remission; PD: Progressive disease; SD: Stable disease.

Table 3 Comparison of liver function in Group A and Group C at the 1^st week after treatment

	Group A	Group C	t/χ2 value	P value
ALB (g/L)	32.82 ± 5.93	31.32 ± 5.28	1.195	0.236
ALT (U/L)	48.29 ± 15.39	67.29 ± 22.93	4.351	0.000
AST (U/L)	51.73 ± 14.92	79.28 ± 20.28	6.921	0.000
TBiL (μmol/L)	23.93 ± 8.38	31.39 ± 9.29	3.771	0.000

ALB: Serum albumin; ALT: Aminotransferase; AST: Aspartate aminotransferase; TBiL: Total bilirubin.

Table 4 Comparison of baseline clinical data between Group A and Group B

	Group A (n = 40)	Group B (n = 36)	t/χ2 value	P value
Gender (Male)	29	26	0.001	0.978
Age (yr)	62.82 ± 12.93	64.82 ± 11.82	0.722	0.472
Tumor size (cm)	3.75 ± 1.21	3.13 ± 0.82	2.683	0.009
Number of tumors			0.002	0.961
Single	22
2-3	18	16
Child-Pugh classification			0.023	0.878
A	26	24
B	14	12
TBiL (μmol/L)	18.28 ± 5.28	17.38 ± 5.62	0.738	0.463
AFP (ng/ml)	612.29 ± 127.38	567.28 ± 92.39	1.746	0.085
ALB (g/L)	37.19 ± 5.39	34.94 ± 4.53	1.958	0.054
ALT (U/L)	35.27 ± 15.14	36.49 ± 12.31	0.383	0.703
AST (U/L)	38.63 ± 15.13	36.22 ± 13.26	0.735	0.465

AFP: Alpha-fetoprotein; ALB: Serum albumin; ALT: Aminotransferase; AST: Aspartate aminotransferase; TBiL: Total bilirubin.